Cascades (CAS) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
27 Mar, 2026Opening remarks and agenda
The Chairman welcomed participants, outlined voting and question procedures, and confirmed notice and proxy materials mailing for the virtual meeting.
The agenda included voting on directors, auditor appointment, executive compensation, shareholder proposals, and a Q&A session.
Board and executive committee updates
The board acknowledged Mario Plourde's retirement after 40 years of leadership in modernization and strategic refocusing.
Eleven director nominees were proposed and elected for the next term.
Management team introduced, including Chairman, CEO, CFO, and Corporate Secretary.
Financial performance review
2024 sales reached CAD 4.7 billion ($4,701M), up 1% from 2023, with EBITDA (A) margin at 10.7% and operating income at $376M.
Adjusted EBITDA fell 10% to CAD 101 million, with margins declining due to higher raw material costs and lower containerboard prices.
Net debt increased to $2,096M (CAD 214 million increase), with a net debt ratio of 4.2x, mainly due to exchange rate impacts and lower profitability.
Capital investments in 2024 were CAD 148 million, 57% lower than the previous year as major projects neared completion.
Q1 2025 sales were $1,154M (CAD 1.15 billion), with operating income of CAD 150 million, adjusted EBITDA up 21% year-over-year, and net earnings per share at $0.07.
Segment performance was mixed, with inflationary pressures and operational repositioning impacting margins.
Latest events from Cascades
- Margins, cash flow, and leverage improved in Q4, with asset sales and EBITDA (A) exceeding targets.CAS
Q4 202527 Feb 2026 - Q2 2024 saw sequential sales and EBITDA(A) growth, higher leverage, and a positive Q3 outlook.CAS
Q2 20242 Feb 2026 - Q3 margin and cash flow improved sequentially, but profit fell year-over-year on higher costs.CAS
Q3 202416 Jan 2026 - Q4 sales and EBITDA rose, but debt and tariff risks weigh on the outlook.CAS
Q4 202423 Dec 2025 - Q1 sales and EBITDA rose year-over-year, with Q2 growth expected despite ongoing trade risks.CAS
Q1 202526 Nov 2025 - Adjusted EBITDA (A) rose 22% year-over-year, but net loss was impacted by a $23M impairment charge.CAS
Q2 202523 Nov 2025 - Q3 2025 delivered robust earnings growth, margin expansion, and improved leverage.CAS
Q3 202513 Nov 2025 - US$400M note issuance to refinance debt and support growth amid strong market positioning.CAS
Investor Presentation1 Jul 2025 - 2024 sales reached $4.7B with EBITDA(A) of $501M, and margin recovery is expected in 2025.CAS
Investor Presentation1 Jul 2025